Two Birds, One Stone: Double Hits on Tumor Growth and Lymphangiogenesis by Targeting Vascular Endothelial Growth Factor Receptor 3

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2019 Mar 24

PMID 30901976

Citations 29

Authors

Ming-Chuan Hsu

Mei-Ren Pan

Wen-Chun Hung

Affiliations

Soon will be listed here.

Abstract

Vascular endothelial growth factor receptor 3 (VEGFR3) has been known for its involvement in tumor-associated lymphangiogenesis and lymphatic metastasis. The VEGFR3 signaling is stimulated by its main cognate ligand, vascular endothelial growth factor C (VEGF-C), which in turn promotes tumor progression. Activation of VEGF-C/VEGFR3 signaling in lymphatic endothelial cells (LECs) was shown to enhance the proliferation of LECs and the formation of lymphatic vessels, leading to increased lymphatic metastasis of tumor cells. In the past decade, the expression and pathological roles of VEGFR3 in tumor cells have been described. Moreover, the VEGF-C/VEGFR3 axis has been implicated in regulating immune tolerance and suppression. Therefore, the inhibition of the VEGF-C/VEGFR3 axis has emerged as an important therapeutic strategy for the treatment of cancer. In this review, we discuss the current findings related to VEGF-C/VEGFR3 signaling in cancer progression and recent advances in the development of therapeutic drugs targeting VEGF-C/VEGFR3.

Citing Articles

Design, synthesis and pharmacological evaluation of 1,4-naphthoquinone- 1,2,3-triazole hybrids as new anticancer agents with multi-kinase inhibitory activity.

Mardaneh P, Pirhadi S, Mohabbati M, Khoshneviszadeh M, Rezaei Z, Saso L Sci Rep. 2025; 15(1):6639.

PMID: 39994286 PMC: 11850817. DOI: 10.1038/s41598-025-87483-w.

Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies.

Calton M, Croze R, Burns C, Beliakoff G, Vazin T, Szymanski P Invest Ophthalmol Vis Sci. 2024; 65(14):1.

PMID: 39620832 PMC: 11614000. DOI: 10.1167/iovs.65.14.1.

Therapeutic advances of targeting receptor tyrosine kinases in cancer.

Tomuleasa C, Tigu A, Munteanu R, Moldovan C, Kegyes D, Onaciu A Signal Transduct Target Ther. 2024; 9(1):201.

PMID: 39138146 PMC: 11323831. DOI: 10.1038/s41392-024-01899-w.

The Alzheimer's disease-linked protease BACE2 cleaves VEGFR3 and modulates its signaling.

Schmidt A, Hrupka B, van Bebber F, Sunil Kumar S, Feng X, Tschirner S J Clin Invest. 2024; 134(16).

PMID: 38888964 PMC: 11324312. DOI: 10.1172/JCI170550.

The pathological roles and potential mechanisms of vascular endothelial growth factor receptor-3 in gastric cancer.

Li X, Zhang X, Hao F, Dong X, Xu G, Zhang Y J Int Med Res. 2024; 52(3):3000605241234558.

PMID: 38518198 PMC: 10960338. DOI: 10.1177/03000605241234558.

References

Zhang Y, Lu Y, Ma L, Cao X, Xiao J, Chen J . Activation of vascular endothelial growth factor receptor-3 in macrophages restrains TLR4-NF-κB signaling and protects against endotoxin shock. Immunity. 2014; 40(4):501-14. DOI: 10.1016/j.immuni.2014.01.013. View

Fernandez Pujol B, Lucibello F, Zuzarte M, Lutjens P, Muller R, Havemann K . Dendritic cells derived from peripheral monocytes express endothelial markers and in the presence of angiogenic growth factors differentiate into endothelial-like cells. Eur J Cell Biol. 2001; 80(1):99-110. DOI: 10.1078/0171-9335-00136. View

Sawano A, Takahashi T, Yamaguchi S, Aonuma M, Shibuya M . Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor. Cell Growth Differ. 1996; 7(2):213-21. View

Bhargava P, Robinson M . Development of second-generation VEGFR tyrosine kinase inhibitors: current status. Curr Oncol Rep. 2011; 13(2):103-11. PMC: 3047052. DOI: 10.1007/s11912-011-0154-3. View

Salven P, Lymboussaki A, Heikkila P, Enholm B, Aase K, von Euler G . Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am J Pathol. 1998; 153(1):103-8. PMC: 1852959. DOI: 10.1016/S0002-9440(10)65550-2. View

Le Bras B, Barallobre M, Homman-Ludiye J, Ny A, Wyns S, Tammela T . VEGF-C is a trophic factor for neural progenitors in the vertebrate embryonic brain. Nat Neurosci. 2006; 9(3):340-8. DOI: 10.1038/nn1646. View

Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao F . Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med. 2002; 8(8):831-40. DOI: 10.1038/nm731. View

Kurenova E, Ucar D, Liao J, Yemma M, Gogate P, Bshara W . A FAK scaffold inhibitor disrupts FAK and VEGFR-3 signaling and blocks melanoma growth by targeting both tumor and endothelial cells. Cell Cycle. 2014; 13(16):2542-53. PMC: 4614818. DOI: 10.4161/15384101.2015.941760. View

Roukens M, Peterson-Maduro J, Padberg Y, Jeltsch M, Leppanen V, Bos F . Functional Dissection of the CCBE1 Protein: A Crucial Requirement for the Collagen Repeat Domain. Circ Res. 2015; 116(10):1660-9. DOI: 10.1161/CIRCRESAHA.116.304949. View

10.

Bierer S, Herrmann E, Kopke T, Neumann J, Eltze E, Hertle L . Lymphangiogenesis in kidney cancer: expression of VEGF-C, VEGF-D and VEGFR-3 in clear cell and papillary renal cell carcinoma. Oncol Rep. 2008; 20(4):721-5. View

11.

Ghalamkarpour A, Morlot S, Raas-Rothschild A, Utkus A, Mulliken J, Boon L . Hereditary lymphedema type I associated with VEGFR3 mutation: the first de novo case and atypical presentations. Clin Genet. 2006; 70(4):330-5. DOI: 10.1111/j.1399-0004.2006.00687.x. View

12.

Virman J, Bono P, Luukkaala T, Sunela K, Kujala P, Kellokumpu-Lehtinen P . VEGFR3 and CD31 as prognostic factors in renal cell cancer. Anticancer Res. 2015; 35(2):921-7. View

13.

Karpanen T, Alitalo K . Lymphatic vessels as targets of tumor therapy?. J Exp Med. 2001; 194(6):F37-42. PMC: 2195960. DOI: 10.1084/jem.194.6.f37. View

14.

Ellis L, Hicklin D . VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008; 8(8):579-91. DOI: 10.1038/nrc2403. View

15.

Yu J, Wu S, Lu R, Wu J, Ni X, Zhou G . Expression and significances of contactin-1 in human gastric cancer. Gastroenterol Res Pract. 2013; 2013:210205. PMC: 3626361. DOI: 10.1155/2013/210205. View

16.

Stewart J, Ma X, Megison M, Nabers H, Cance W, Kurenova E . Inhibition of FAK and VEGFR-3 binding decreases tumorigenicity in neuroblastoma. Mol Carcinog. 2013; 54(1):9-23. PMC: 4370318. DOI: 10.1002/mc.22070. View

17.

Sternberg C, Davis I, Mardiak J, Szczylik C, Lee E, Wagstaff J . Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010; 28(6):1061-8. DOI: 10.1200/JCO.2009.23.9764. View

18.

Kerjaschki D, Regele H, Moosberger I, Nagy-Bojarski K, Watschinger B, Soleiman A . Lymphatic neoangiogenesis in human kidney transplants is associated with immunologically active lymphocytic infiltrates. J Am Soc Nephrol. 2004; 15(3):603-12. DOI: 10.1097/01.asn.0000113316.52371.2e. View

19.

Misawa Y, Misawa K, Kawasaki H, Imai A, Mochizuki D, Ishikawa R . Evaluation of epigenetic inactivation of vascular endothelial growth factor receptors in head and neck squamous cell carcinoma. Tumour Biol. 2017; 39(7):1010428317711657. DOI: 10.1177/1010428317711657. View

20.

Skobe M, Hawighorst T, Jackson D, Prevo R, Janes L, Velasco P . Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med. 2001; 7(2):192-8. DOI: 10.1038/84643. View